Special Interest Groups
EFOMP “Radionuclide Internal Dosimetry”.
Therapeutic applications in nuclear medicine are developing rapidly. They use a growing range of radiolabelled vectors (simple vector molecules, peptides, antibodies) and medical devices (radioactive microspheres). Various radioactive nuclides (beta, but also alpha or Auger) are also considered. Due to this variety, the characterisation of the irradiation delivered to the patient is at the same time stimulating and challenging. Yet, reliable absorbed dose calculations are now
available thanks to technological and scientific developments of the last decades.
An increasing number of patients will benefit from treatment with radiotherapeutics, since therapeutic agents recently developed or in early phase trials are able to treat more common
cancers, including liver colorectal metastases or prostate cancer. However, the role of patient- specific dosimetry in therapeutic nuclear medicine is still, astonishingly, a matter of discussion, despite regulations: treatment planning and/or verification of the irradiation delivered during nuclear medicine therapy are seldom performed in clinical practice, even though they correspond to a legal requirement (Basic Safety Standard Council Directive EURATOM 2013/59).
The role of the medical physics expert (MPE) in nuclear medicine dosimetry was presented in EFOMP Policy Statement 16. However, the availability of physicists able to implement clinical dosimetry is still severely limited. Furthermore, the important shortage in medical physics resources within the European Union is more pronounced in nuclear medicine dosimetry.
The objective of the SIG for Radionuclide Internal Dosimetry is to establish a network of medical physicists working in radionuclide dosimetry. The SIG aims to fulfil the need for networking, education, research and professional exchanges in this field.
The SIG is a permanent structure. SIG members participate in the different working groups via a specific mail list. The SIG for radionuclide internal dosimetry was officially created in February 2021. The kick-off meeting took place on was held on 8th March 2021 and defined the following priorities:
Setup a survey on the status of clinical dosimetry in NMOs
Collect and propose free dosimetry resources
Collect education schemes (academic and clinical training) in NMOs
Disseminate information on radionuclide internal dosimetry events
Address specific scientific questions on radionuclide internal dosimetry
Promote the participation to European (Horizon) activities
Raise awareness about the need for internal dosimetry in clinical routine
All EFOMP members can individually apply to be a member of this SIG electronically using the attached SIG member application form. NMOs can also nominate representatives. A professional CV is required.
Applications can be sent anytime to: firstname.lastname@example.org
The Steering Committee members elected during the kick-off meeting are:
Manuel Bardiès, Montpellier, France
Gerhard Glatting, Ulm, Germany
Ernesto Amato, Messina, Italy
Carlo Chiesa, Milano, Italy
Steffie Peters, Radboud, Netherlands
Caroline Stokke, Oslo, Norway
Pablo Minguez Gabiña, Bilbao, Spain
Glenn Flux, Sutton, UK
Ana Denis Bacelar, Teddington, UK
Chair: Manuel Bardiès, Montpellier, France
Vice-Chair: Steffie Peters, Radboud, Netherlands
Secretary: Ernesto Amato, Messina, Italy